Emergence of unusual nonfermenting Gram-negative nosocomial pathogens in a Saudi hospital

Japanese Journal of Infectious Diseases

Volumn 66, Issue 6, 2013, Pages 507-511

  Morad Asaad, Ahmed ^a   Zayed Al Ayed, Mohamed Said ^a   Ansar Qureshi, Mohamed ^a  

^a NAJRAN UNIVERSITY   (Saudi Arabia)

Author keywords

Acinetobacter; Alcaligenes; Chryseobacterium; Ralstonia; Stenotrophomonas

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ALCALIGENES FAECALIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BROTH DILUTION; CHRYSEOBACTERIUM INDOLOGENES; DISEASE PREDISPOSITION; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONFERMENTING GRAM NEGATIVE BACTERIUM; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; RALSTONIA PICKETTII; SAUDI ARABIA; STENOTROPHOMONAS MALTOPHILIA; TERTIARY HEALTH CARE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES, EMERGING; CROSS INFECTION; CROSS-SECTIONAL STUDIES; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SAUDI ARABIA; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84888122690     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.66.507     Document Type: Article

References (27)

1. Enoch, D.A., Birkett, C.I. and Ludlam, H.A. (2007): Non fermentative Gram-negative bacteria. Int. J. Antimicrob. Agents, 29, S33-S41.
2. McGowan, J.E. (2006): Resistance in non-fermenting Gramnegative bacteria: multidrug resistance to the maximum. Am. J. Med., 119, S29-S36.
3. Jacquier, H.E., Carbonnelle, S., Corvec, M., et al. (2011): Revisited distribution of non fermenting Gram-negative bacilli clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis., 30, 579-586.
4. Gales, A.C., Jones, R.N., Andrade, S.S., et al (2005): Antimicrobial susceptibility patterns of unusual non fermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). Mem. Inst. Oswaldo Cruz, 100, 571-577.
5. Sader, H.S. and Jones, R.N. (2005): Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int. J. Antimicrob. Agents, 25, 95-109.
6. Steinberg, J.P. and Del Rio, C. (2000): Other gram-negative bacilli. p. 2459-247. In G.L. Mandell, J.E. Bennet and R. Dolin (ed.), Mandell's Principles and Practice of Infectious Diseases. Churchill Livingstone, Philadelphia, Pa.
7. Jones, C.M. and Livermore, D.M. (2009): Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other non fermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis., 63, 426-433.
8. Quale, J., Bratu, S., Landman, D., et al. (2003): Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis., 37, 214-220.
9. Qin, X., Emerson, J., Stapp, J., et al. (2003): Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other non fermenting Gram-negative bacilli from patients with cystic fibrosis. J. Clin. Microbiol., 41, 4312-4317.
10. Gales, A.C., Jones, R.N., Forward, K.R., et al. (2001): Emerging importance of multi-drug resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in severely ill patients: geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis., 32, 104-113.
11. Fihman, V., Le Monnier, A., Corvec, S., et al. (2012): Stenotrophomonas maltophilia-the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J. Infect., 64, 391-398.
12. Chen, Y.H., Hsueh, P.R., Badal, R.E., et al. (2011): Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J. Infect., 62, 280-291.
13. Horan, T.C., Andrus, M. and Dudeck, M.A. (2008): CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control, 36, 309-332.
14. Murray, P.R., Baron, E.J., Pfaller, M.A., et al. (2003): Manual of Clinical Microbiology Handbook. Washington, D.C.
15. Clinical and Laboratory Standards Institute (2012): Performance Standards for Antimicrobial Susceptibility Testing: 22nd Informational Supplement. M100-S22. CLSI, Wayne, Pa.
16. Cervia, J.S., Ortolano, G.A. and Canonica, F.P. (2008): Hospital tap water as a source of Stenotrophomonas maltophilia infection. Clin. Infect. Dis., 46, 1485-1487.
17. Abdalla, N.M., Osman, A.A., Haimour, W.O., et al. (2013): Antimicrobial susceptibility pattern in nosocomial infections caused by Acinetobacter species in Asir region, Saudi Arabia. Pak. J. Biol. Sci., 16, 275-280.
18. Al-Tawfiq, J.A. and Mohandhas, T.X. (2007): Prevalence of antimicrobial resistance in Acinetobacter calcoaceticus-baumannii complex in a Saudi Arabian hospital. Infect. Control Hosp. Epidemiol., 28, 870-872.
19. Memish, Z.A., Shibl, A.M., Kambal, A.M., et al. (2012): Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia. J. Antimicrob. Chemother., 67, 1701-1705.
20. Gales, A.C., Jones, R.N. and Sader, H.S. (2006): Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect., 12, 315-321.
21. San Gabriel, P., Zhou, J., Tabibi, S., et al. (2004): Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother., 28, 168-171.
22. Tsiodras, S., Pittet, D., Carmeli, Y., et al. (2000): Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand. J. Infect. Dis., 32, 651-656.
23. Al-Jasser, A.M. (2006): Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann. Clin. Microbiol. Antimicrob., 5, 23-25.
24. Farrell, D.J., Sader, H.S. and Jones, R.N. (2010): Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob. Agents Chemother., 54, 2735-2737.
25. Wu, H.A., Wang, J., Shiau, Y., et al. (2012): A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J. Microbiol. Immunol. Infect., 45, 120-126.
26. Hsueh, P.R., Teng, L.J., Ho, S.W., et al. (1996): Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices. J. Clin. Microbiol., 34, 1908-1913.
27. T'Sjoen, G., Verschraegen, G., Steyaert, S., et al. (2001): Avoidable fever of unknown origin due to Ralstonia pickettii bacteremia. Acta Clin. Belg., 56, 51-54.